Pricing methods in outcome-based contracting: δ3: reference-based pricing
- 8 September 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (11) , 1230-1236
Abstract
Aims: Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The third dimension (δ3) estimates prices on the basis of international drug price referencing methods. We describe this dimension’s methodology and present a proof-of-concept application to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation with osimertinib. Materials and methods: The reference-based pricing dimension utilizes a six-step method: 1) selecting foreign countries based on a set of four criteria (drug is available in the foreign country, price information is available in the foreign country, foreign countries are members within the organization for Economic Co-operation and Development, pricing methods in the foreign countries involve value assessment); 2) adjusting for exchange rates; 3) generating reference price (RP) scenarios; 4) adjusting with the medical inflation rate; 5) pooling all generated RP scenarios and calculating average and standard deviation (SD); 6) and Monte Carlo Simulation (MCS) to estimate the dimension-specific DSPReference. A proof-of-concept exercise with osimertinib in NSCLC was performed for two hypothetical outcome-based contracts: 1-year (2019-2020) and 2-year (2019-2021). Results: The United Kingdom and Canada met the four criteria. For the osimertinib 1-year contract price, the average of eight RP scenarios, adjusted for inflation by 0.44%, was $8,892 (SD=$2,606) for a 30-day prescription. MCS yielded a DSPReference estimate of $9,395 or -35.72% of the wholesale acquisition cost (WAC) of $14,616. For the 2-year contract, the average, adjusted for inflation by 0.72%, was $8,928 (SD=$2,610). MCS yielded a DSPReference estimate of $9,442 or -35.40% of the WAC of $14,616. Conclusions: We demonstrated that international price referencing methods can be integrated into our proposed Six Delta platform for outcome-based pricing/contracting.Keywords
This publication has 7 references indexed in Scilit:
- Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricingJournal of Medical Economics, 2020
- Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricingJournal of Medical Economics, 2020
- Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in CanadaLung Cancer, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancerJournal of Medical Economics, 2017
- Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New DrugsHealth Affairs, 2013
- Impact of Cross-Reference Pricing on Pharmaceutical PricesApplied Health Economics and Health Policy, 2006